Abnormal phagocyte chemotaxis: pathophysiology, clinical manifestations, and management of patients.
D000917:Antibody Formation; D001205:Ascorbic Acid / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002448:Cell Adhesion; D002464:Cell Migration Inhibition; D002465:Cell Movement; D002630:Chemotactic Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D002634:Chemotaxis, Leukocyte; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy; D007111:Immunity, Cellular; D007073:Immunoglobulin E / Q000276:immunology; D007978:Levamisole / Q000627:therapeutic use; D008264:Macrophages; D008297:Male; D009000:Monocytes / Q000502:physiology; D009504:Neutrophils / Q000502:physiology; D010586:Phagocytes / Q000502:physiology*; D014131:Trace Elements / Q000627:therapeutic use
D002630:Chemotactic Factors; D014131:Trace Elements; D007978:Levamisole; D007073:Immunoglobulin E; D001205:Ascorbic Acid